{"id":836,"date":"2026-08-05T16:50:26","date_gmt":"2026-08-05T08:50:26","guid":{"rendered":"https:\/\/vitiligo.skinmedical.com.hk\/evidence-based-treatment02\/"},"modified":"2026-08-12T17:43:45","modified_gmt":"2026-08-12T09:43:45","slug":"evidence-based-treatment02","status":"publish","type":"page","link":"https:\/\/vitiligo.skinmedical.com.hk\/en\/evidence-based-treatment02\/","title":{"rendered":"Evidence-based treatment (Part 2)"},"content":{"rendered":"
<\/div>

Vitiligo<\/span><\/h2>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div>

Evidence-based treatment (Part 2)<\/span><\/strong><\/h3>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div>

Three goals, in order: stop the spread<\/strong>, restore pigment<\/strong>, prevent relapse<\/strong>. Most treatment plans combine two or more approaches, because combinations consistently outperform single agents.<\/span><\/p>\n

 <\/p>\n

Summary table<\/strong><\/span><\/p>\n<\/div><\/div>

\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Treatment<\/span><\/strong><\/span><\/td>\nBest suited to<\/span><\/strong><\/span><\/td>\nEvidence<\/span><\/strong><\/span><\/td>\nTime to visible response<\/span><\/strong><\/span><\/td>\n<\/tr>\n
Sun protection & camouflage<\/span><\/strong><\/span><\/td>\nAll patients<\/span><\/td>\nStrong (protective), high patient satisfaction<\/span><\/td>\nImmediate (camouflage)<\/span><\/td>\n<\/tr>\n
Topical corticosteroids<\/span><\/strong><\/span><\/td>\nLimited disease, body sites<\/span><\/td>\nWell established<\/span><\/td>\n2\u20133 months<\/span><\/td>\n<\/tr>\n
Topical calcineurin inhibitors<\/span><\/strong><\/span><\/td>\nFace, neck, folds; children; maintenance<\/span><\/td>\nStrong; first line for facial disease<\/span><\/td>\n2\u20134 months<\/span><\/td>\n<\/tr>\n
Topical JAK inhibitor cream<\/span><\/strong><\/span><\/td>\nNon-segmental vitiligo with facial involvement, age 12+<\/span><\/td>\nRandomised controlled trial evidence; registered in HK<\/span><\/td>\n3\u20136 months, continuing to 12 months<\/span><\/td>\n<\/tr>\n
Narrowband UVB<\/span><\/strong><\/span><\/td>\nWidespread or progressive disease<\/span><\/td>\nStrongest evidence for extensive disease<\/span><\/td>\n3 months minimum; treat 6\u201312 months<\/span><\/td>\n<\/tr>\n
308nm excimer<\/span><\/strong><\/span><\/td>\nLocalised disease, under ~10% body surface<\/span><\/td>\nStrong for localised disease; faster than whole-body UVB<\/span><\/td>\n1\u20133 months<\/span><\/td>\n<\/tr>\n
Oral mini-pulse steroids<\/span><\/strong><\/span><\/td>\nRapidly spreading disease<\/span><\/td>\nModerate; used to arrest progression<\/span><\/td>\n1\u20133 months to halt spread<\/span><\/td>\n<\/tr>\n
Oral JAK inhibitors<\/span><\/strong><\/span><\/td>\nExtensive disease unresponsive to the above<\/span><\/td>\nPhase 3 data; under regulatory review, currently off-label<\/span><\/td>\n6\u201312 months<\/span><\/td>\n<\/tr>\n
Surgical grafting<\/span><\/strong><\/span><\/td>\nStable segmental or focal disease, stable \u226512 months<\/span><\/td>\nStrong in correctly selected patients<\/span><\/td>\n2\u20136 months<\/span><\/td>\n<\/tr>\n
Adjunctive (fractional laser, PRP, oral antioxidants)<\/span><\/strong><\/span><\/td>\nResistant sites, as an add-on only<\/span><\/td>\nLow to moderate quality<\/span><\/td>\nVariable<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>
<\/div>
\"Vitiligo_treatment_medication\"<\/div><\/div>